Boehringer Ingelheim’s Post

Venture investment in biopharma and medtech companies hits new highs in Q2. Learn more from our experts Kathryn McDonough and Skip Kelly on the latest trends and insights in our reports, powered by DealForma: https://lnkd.in/en4rSKRf #JPMInnovationEconomy

Explore our latest quarterly report for an in-depth look at the dynamic biotech landscape over the past few months 🚀. The biotech sector remains a vibrant hub of innovation and strategic partnerships, propelling scientific progress and discoveries.

Amidst challenges, venture investment in biopharma and medtech companies trend up. Learn more from our industry executives Kathryn McDonough and Skip Kelly in our Q1 reports, powered by DealForma. Read the reports here: https://lnkd.in/eN_5Y6GK

Insightful report on the rebounding Biopharma and Medtech venture investment activity in Q1. On track to outpace 2023 with interest rates stabilized and potential for rate cuts later this year.

Are you a biotech co having trouble "breaking through the noise" (a.k.a. capturing investors' attention)? Check out this analysis 📊📈🔍from our editor-in-chief: "Rising above the noise: hallmarks of Europe’s leading innovation - Business models, technologies and management profiles of European companies that attracted investor or pharma interest during the downturn" Details here: https://lnkd.in/gcJjKcs7 [sub/trial access required] Great insights. Fantastic visuals in the slide deck.

🌟 Dive into the Latest Insights on our NOW Page 47 – June 2024! Discover groundbreaking updates, inspiring thoughts, and future-forward innovations that you can't afford to miss. Click here to explore: https://lnkd.in/gpiZSf74 🚀 #Innovation #FutureReady #PolyInnovator

How can emerging biotech companies develop a commercial value story to differentiate their product and attract funding? Our white paper provides a comprehensive guide on how to unlock a framework for integrating commercial and clinical insights and ensure a compelling value story for investors. Learn more: https://ow.ly/UJis30sAe53 #SyneosHealth

A nice snapshot to highlight the dispersion of innovation in Europe today. And at a time when Axial is re-engaging with the small cap IPO market (the long winter in the capital markets brightening at last!) the key drivers are proving to be business fundamentals (as should always have been the case in our view) and ideally patented IP.

A rebounding M&A environment, AI investments for productivity and cost reduction, and innovations in digital health and biotechnology were among top themes at the Morgan Stanley Global Healthcare Conference. Learn more below about potential opportunities for investors.

 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐧𝐨𝐰: https://lnkd.in/eeHtkcBJ Join me 𝐋𝐈𝐕𝐄 on 26th September at 11 AM GMT as I share my blueprint for breakthrough innovation. Take benefit of a 𝐥𝐢𝐯𝐞 𝐐&𝐀 session to address 𝐲𝐨𝐮𝐫 specific 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬!